Board Certified Pharmacotherapy Specialist (BCPS®) Exam
2026 Latest Comprehensive Study Guide with Practice
Questions Pharmacotherapy Review • Detailed Rationales •
Verified Answers • Success Workbook
Domain Percentage
1. Patient-Centered Pharmacotherapy ~55%
2. Drug Information and Literature Evaluation / Population
~17%
Health
3. System-based Practice and Quality ~12%
4. Public Health and Wellness ~16%
Domain 1: Patient-Centered Pharmacotherapy is the highest-weighted domain
and includes:
• Developing evidence-based pharmacotherapy plans
• Monitoring for safe and effective therapy
• Modifying plans through ongoing patient assessment
• Communicating plans to patients and caregivers
• Educating patients on safe medication use
Domain 2: Application of Evidence to Practice and Education includes:
• Retrieving pharmacotherapy-related information
• Evaluating literature and health information
• Biostatistics and study design
Eligibility Requirements:
, • Pharmacy degree from an ACPE-accredited program
• PLUS one of: 3 years of practice with ≥50% in pharmacotherapy, an ASHP-
accredited PGY1 residency, or a PGY2 residency
How to Use This Guide:
• Answer each question without looking at the rationale first
• Review the detailed rationale for both correct and incorrect answers
• Identify your weak areas and focus additional study time there
• Aim for 80% or higher on practice questions before scheduling your exam
DOMAIN 1: PATIENT-CENTERED PHARMACOTHERAPY
Cardiology & Anticoagulation
Question 1
A 62-year-old male with a history of heart failure with reduced ejection fraction
(HFrEF, EF 30%) is being treated with lisinopril, carvedilol, and furosemide. His
blood pressure is 118/72 mmHg, heart rate 68 bpm, and serum potassium 4.8
mEq/L. Which of the following is the most appropriate addition to his regimen?
A) Digoxin 0.125 mg daily
B) Sacubitril/valsartan 97/103 mg twice daily
C) Spironolactone 25 mg daily
D) Amlodipine 5 mg daily
Rationale: Sacubitril/valsartan (Entresto) is indicated for HFrEF and has been
shown to reduce cardiovascular death and heart failure hospitalizations compared
to enalapril. The patient is already on an ACE inhibitor (lisinopril), beta-blocker
(carvedilol), and diuretic, making him a candidate for sacubitril/valsartan. The
ACE inhibitor would need to be discontinued (with a 36-hour washout) before
starting sacubitril/valsartan to avoid angioedema. Spironolactone could be
considered but is not the first-line addition. Digoxin is reserved for persistent
symptoms despite optimal therapy or for rate control in atrial fibrillation.
,Question 2
A 55-year-old female with paroxysmal atrial fibrillation and a CHA₂DS₂-VASc
score of 3 is being started on anticoagulation. She has a creatinine clearance of 45
mL/min. Which of the following is the most appropriate anticoagulant?
A) Warfarin with target INR 2-3
B) Apixaban 5 mg twice daily
C) Dabigatran 150 mg twice daily
D) Rivaroxaban 20 mg daily
Rationale: Apixaban is appropriate for this patient. For apixaban 5 mg BID, dose
reduction to 2.5 mg BID is recommended if the patient has at least two of the
following: age ≥80, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. This patient
has none of these criteria. Dabigatran 150 mg BID is not recommended for CrCl
<50 mL/min (it would require 75 mg BID with FDA labeling, though European
guidelines differ). Rivaroxaban 20 mg daily is not recommended for CrCl <50
mL/min (dose reduction to 15 mg daily is recommended). Warfarin is effective but
DOACs are preferred for non-valvular AF due to superior safety and convenience.
Question 3
A 68-year-old male with a history of deep vein thrombosis (DVT) is being treated
with warfarin. His INR is 5.2, and he has no signs of bleeding. What is the most
appropriate management?
A) Hold warfarin and administer vitamin K 2.5 mg orally
B) Hold warfarin and resume when INR <5.0
C) Hold warfarin and administer fresh frozen plasma
D) Decrease warfarin dose by 25%
Rationale: For an asymptomatic patient with INR between 5.0 and 9.0, the
standard recommendation is to hold warfarin and resume when INR is <5.0.
Vitamin K is not routinely recommended unless the INR is >10 or there is
bleeding. Fresh frozen plasma is reserved for life-threatening bleeding. Decreasing
the dose without holding is not appropriate for an INR of 5.2.
Question 4
A 72-year-old female with non-valvular atrial fibrillation is started on apixaban for
, stroke prophylaxis. Which of the following would require a dose reduction to 2.5
mg twice daily?
A) Age 72, weight 75 kg, CrCl 55 mL/min
B) Age 82, weight 58 kg, CrCl 60 mL/min
C) Age 78, weight 65 kg, CrCl 45 mL/min
D) Age 70, weight 55 kg, CrCl 35 mL/min
Rationale: Apixaban dose reduction to 2.5 mg BID is recommended if the patient
has at least TWO of the following: age ≥80, weight ≤60 kg, or serum creatinine
≥1.5 mg/dL. Option B has age 82 (≥80) AND weight 58 kg (≤60), meeting the
criteria for dose reduction. Option C has age 78 (not ≥80) and CrCl is not the
criterion (serum creatinine ≥1.5 mg/dL is). Option D has weight ≤60 kg but age 70
(not ≥80).
Question 5
A 60-year-old male with heart failure with preserved ejection fraction (HFpEF)
and hypertension is being evaluated for optimal blood pressure management.
Which of the following is the most appropriate first-line antihypertensive?
A) Amlodipine
B) Spironolactone
C) Lisinopril
D) Metoprolol
Rationale: Spironolactone has been shown to reduce heart failure hospitalizations
in patients with HFpEF. While ACE inhibitors, ARBs, and beta-blockers are used,
spironolactone has specific evidence in HFpEF (TOPCAT trial). The goal blood
pressure for HFpEF patients is <130/80 mmHg. Diuretics are also important for
volume management.
Question 6
A 45-year-old male is being evaluated for statin therapy. He has a 10-year ASCVD
risk of 12%. His LDL is 145 mg/dL. According to the 2018 ACC/AHA Cholesterol
Guidelines, which of the following is the most appropriate recommendation?
A) Lifestyle modifications only
B) Moderate-intensity statin
2026 Latest Comprehensive Study Guide with Practice
Questions Pharmacotherapy Review • Detailed Rationales •
Verified Answers • Success Workbook
Domain Percentage
1. Patient-Centered Pharmacotherapy ~55%
2. Drug Information and Literature Evaluation / Population
~17%
Health
3. System-based Practice and Quality ~12%
4. Public Health and Wellness ~16%
Domain 1: Patient-Centered Pharmacotherapy is the highest-weighted domain
and includes:
• Developing evidence-based pharmacotherapy plans
• Monitoring for safe and effective therapy
• Modifying plans through ongoing patient assessment
• Communicating plans to patients and caregivers
• Educating patients on safe medication use
Domain 2: Application of Evidence to Practice and Education includes:
• Retrieving pharmacotherapy-related information
• Evaluating literature and health information
• Biostatistics and study design
Eligibility Requirements:
, • Pharmacy degree from an ACPE-accredited program
• PLUS one of: 3 years of practice with ≥50% in pharmacotherapy, an ASHP-
accredited PGY1 residency, or a PGY2 residency
How to Use This Guide:
• Answer each question without looking at the rationale first
• Review the detailed rationale for both correct and incorrect answers
• Identify your weak areas and focus additional study time there
• Aim for 80% or higher on practice questions before scheduling your exam
DOMAIN 1: PATIENT-CENTERED PHARMACOTHERAPY
Cardiology & Anticoagulation
Question 1
A 62-year-old male with a history of heart failure with reduced ejection fraction
(HFrEF, EF 30%) is being treated with lisinopril, carvedilol, and furosemide. His
blood pressure is 118/72 mmHg, heart rate 68 bpm, and serum potassium 4.8
mEq/L. Which of the following is the most appropriate addition to his regimen?
A) Digoxin 0.125 mg daily
B) Sacubitril/valsartan 97/103 mg twice daily
C) Spironolactone 25 mg daily
D) Amlodipine 5 mg daily
Rationale: Sacubitril/valsartan (Entresto) is indicated for HFrEF and has been
shown to reduce cardiovascular death and heart failure hospitalizations compared
to enalapril. The patient is already on an ACE inhibitor (lisinopril), beta-blocker
(carvedilol), and diuretic, making him a candidate for sacubitril/valsartan. The
ACE inhibitor would need to be discontinued (with a 36-hour washout) before
starting sacubitril/valsartan to avoid angioedema. Spironolactone could be
considered but is not the first-line addition. Digoxin is reserved for persistent
symptoms despite optimal therapy or for rate control in atrial fibrillation.
,Question 2
A 55-year-old female with paroxysmal atrial fibrillation and a CHA₂DS₂-VASc
score of 3 is being started on anticoagulation. She has a creatinine clearance of 45
mL/min. Which of the following is the most appropriate anticoagulant?
A) Warfarin with target INR 2-3
B) Apixaban 5 mg twice daily
C) Dabigatran 150 mg twice daily
D) Rivaroxaban 20 mg daily
Rationale: Apixaban is appropriate for this patient. For apixaban 5 mg BID, dose
reduction to 2.5 mg BID is recommended if the patient has at least two of the
following: age ≥80, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. This patient
has none of these criteria. Dabigatran 150 mg BID is not recommended for CrCl
<50 mL/min (it would require 75 mg BID with FDA labeling, though European
guidelines differ). Rivaroxaban 20 mg daily is not recommended for CrCl <50
mL/min (dose reduction to 15 mg daily is recommended). Warfarin is effective but
DOACs are preferred for non-valvular AF due to superior safety and convenience.
Question 3
A 68-year-old male with a history of deep vein thrombosis (DVT) is being treated
with warfarin. His INR is 5.2, and he has no signs of bleeding. What is the most
appropriate management?
A) Hold warfarin and administer vitamin K 2.5 mg orally
B) Hold warfarin and resume when INR <5.0
C) Hold warfarin and administer fresh frozen plasma
D) Decrease warfarin dose by 25%
Rationale: For an asymptomatic patient with INR between 5.0 and 9.0, the
standard recommendation is to hold warfarin and resume when INR is <5.0.
Vitamin K is not routinely recommended unless the INR is >10 or there is
bleeding. Fresh frozen plasma is reserved for life-threatening bleeding. Decreasing
the dose without holding is not appropriate for an INR of 5.2.
Question 4
A 72-year-old female with non-valvular atrial fibrillation is started on apixaban for
, stroke prophylaxis. Which of the following would require a dose reduction to 2.5
mg twice daily?
A) Age 72, weight 75 kg, CrCl 55 mL/min
B) Age 82, weight 58 kg, CrCl 60 mL/min
C) Age 78, weight 65 kg, CrCl 45 mL/min
D) Age 70, weight 55 kg, CrCl 35 mL/min
Rationale: Apixaban dose reduction to 2.5 mg BID is recommended if the patient
has at least TWO of the following: age ≥80, weight ≤60 kg, or serum creatinine
≥1.5 mg/dL. Option B has age 82 (≥80) AND weight 58 kg (≤60), meeting the
criteria for dose reduction. Option C has age 78 (not ≥80) and CrCl is not the
criterion (serum creatinine ≥1.5 mg/dL is). Option D has weight ≤60 kg but age 70
(not ≥80).
Question 5
A 60-year-old male with heart failure with preserved ejection fraction (HFpEF)
and hypertension is being evaluated for optimal blood pressure management.
Which of the following is the most appropriate first-line antihypertensive?
A) Amlodipine
B) Spironolactone
C) Lisinopril
D) Metoprolol
Rationale: Spironolactone has been shown to reduce heart failure hospitalizations
in patients with HFpEF. While ACE inhibitors, ARBs, and beta-blockers are used,
spironolactone has specific evidence in HFpEF (TOPCAT trial). The goal blood
pressure for HFpEF patients is <130/80 mmHg. Diuretics are also important for
volume management.
Question 6
A 45-year-old male is being evaluated for statin therapy. He has a 10-year ASCVD
risk of 12%. His LDL is 145 mg/dL. According to the 2018 ACC/AHA Cholesterol
Guidelines, which of the following is the most appropriate recommendation?
A) Lifestyle modifications only
B) Moderate-intensity statin
